logo

Latin America Alpha-Glucosidase Inhibitors Market Size (2024 - 2029)

The Latin America Alpha-Glucosidase Inhibitors market is anticipated to experience growth over the forecast period, driven by the increasing prevalence of Type-2 diabetes in the region. The high diabetic population, particularly in countries like Mexico, is a significant factor contributing to the expansion of this market. Despite challenges posed by the COVID-19 pandemic and inadequate protective measures for diabetics in many Latin American countries, the demand for Alpha-Glucosidase Inhibitors is expected to rise, influencing the market size positively during the forecast period.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Inhibitors Research Alpha-Glucosidase Inhibitors Market in Latin America Market Size

Market Size of Latin America Alpha-Glucosidase Inhibitors Industry

Latin America Alpha-Glucosidase Inhibitors Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 3.30 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Latin America Alpha-Glucosidase Inhibitors Market Analysis

The Latin America Alpha-Glucosidase Inhibitors Market size is expected to grow from USD 72.47 million in current year to USD 85.24 million by forecast year, at a CAGR of 3.30% during the forecast period.

The COVID-19 pandemic has been testing the capacity to respond and adapt to populations, governments, and health systems worldwide. In the Latin America region, Brazil presented the first suspected and the first confirmed cases on January 27th and February 26th, respectively. Most Latin American countries failed to implement timely measures to protect individuals with diabetes, which may severely impact individuals, health systems, and economies.

The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, is acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, close to 10% of the total population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, and they accounted for close to 90% of the total diabetic population in 2021.

This is driving the demand for Alpha-Glucosidase Inhibitors in Latin America, thereby driving the market in focus during the forecast period.

Latin America Alpha-Glucosidase Inhibitors Industry Segmentation

Alpha-glucosidase inhibitors prevent the small intestine from absorbing carbs. They block enzymes that convert complicated non-absorbable carbs into simple absorbable carbohydrates by competitive inhibition. The Latin America Alpha-Glucosidase Inhibitors Market is segmented by by Drug (Alpha-Glucosidase Inhibitors) and Geography (Brazil, Mexico, and the Rest of Latin America). The report offers the value (in USD) and Volume (in Unit) for the above segments.

Drug
Alpha-glucosidase Inhibitors
Geography
Brazil
Mexico
Rest of Latin America
Need A Different Region Or Segment?
Customize Now

Latin America Alpha-Glucosidase Inhibitors Market Size Summary

The Latin America Alpha-Glucosidase Inhibitors Market is poised for growth, driven by the high prevalence of Type-2 diabetes in the region, particularly in countries like Mexico and Brazil. The increasing rates of obesity and genetic predisposition have contributed to a significant rise in diabetic patients, with Type-2 diabetes accounting for the majority of cases. The demand for Alpha-Glucosidase Inhibitors is expected to rise as these medications play a crucial role in managing blood sugar levels and improving metabolic profiles without causing serious side effects. The market's expansion is further supported by the healthcare infrastructure in Brazil, which offers various programs to enhance access to essential medicines and primary healthcare, despite challenges such as late diagnosis and high treatment costs.

The market landscape is characterized by a high degree of fragmentation, with key players like Bayer, SunPharma, Pfizer, and Takeda actively participating in the region. These companies are involved in ongoing research and development efforts, including drug repurposing studies to optimize existing FDA-approved drugs for better efficacy against α-glucosidase. Regulatory actions, such as price fixing by the National Pharmaceutical Pricing Authority, also influence market dynamics. The interdisciplinary approach to managing Type-2 diabetes, involving primary care providers, pharmacists, and nurse practitioners, is essential for patient education and dietary management, further supporting the market's growth trajectory during the forecast period.

Explore More

Latin America Alpha-Glucosidase Inhibitors Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Drivers

    3. 1.3 Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. Market Segmentation

    1. 2.1 Drug

      1. 2.1.1 Alpha-glucosidase Inhibitors

    2. 2.2 Geography

      1. 2.2.1 Brazil

      2. 2.2.2 Mexico

      3. 2.2.3 Rest of Latin America

Latin America Alpha-Glucosidase Inhibitors Market Size FAQs

The Latin America Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 3.30% during the forecast period (2024-2029)

Takeda, Pfizer, Bayer, Sun Pharma and Glenmark are the major companies operating in the Latin America Alpha-Glucosidase Inhibitors Market.

Latin America Alpha-Glucosidase Inhibitors Market Report Snapshots

Latin America Alpha-Glucosidase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)